ResearcherDuke Medical CenterNo recent work listed

Benjamin L. Lampson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6033-3363; OpenAlex author ID A5017380326. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper

Papers 2

Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer. First author DOI 10.1371/journal.pone.0140253 ↗
Targeting eNOS in pancreatic cancer. Co-author DOI 10.1158/0008-5472.can-12-0057 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Christopher M Counter · 2 shared papers, 2012–2015 · strength 0.09
- Paper Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Ca… DOI 10.1371/journal.pone.0140253 ↗
- Paper Targeting eNOS in pancreatic cancer. DOI 10.1158/0008-5472.can-12-0057 ↗
Jamie D. Weyandt · 1 shared paper, 2015 · strength 0.06
- Paper Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Ca… DOI 10.1371/journal.pone.0140253 ↗
David F. Kashatus · 1 shared paper, 2012 · strength 0.03
- Paper Targeting eNOS in pancreatic cancer. DOI 10.1158/0008-5472.can-12-0057 ↗
Rebekah Ruth White · 1 shared paper, 2012 · strength 0.03
- Paper Targeting eNOS in pancreatic cancer. DOI 10.1158/0008-5472.can-12-0057 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.